FDA advisers vote against sleep peptide as they debate safety and health claims
An FDA advisory committee is meeting for two days to discuss whether seven peptides — which have become popular in wellness circles — should be allowed to be compounded.
An FDA advisory committee is meeting for two days to discuss whether seven peptides — which have become popular in wellness circles — should be allowed to be compounded.
Summary aggregated from MarketWatch's public RSS feed. The full reporting belongs to MarketWatch — please read it on their site.